deaths (OS)

Extensive stage SCLC (Es-SCLC) - 1st Line (L1) Extensive stage SCLC (Es-SCLC) Extensive stage SCLC (Es-SCLC) - 1st Line (L1)

versus etoposide plus platin
durvalumab plus tremelimumab plus SoC vs. etoposide plus platin 1 0.82 [0.68; 0.99], 1 RCT, I2=0%
unassessable degree of certainty